Clinical OMICS

JAN-FEB 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 13 of 51

12 Clinical OMICs January/February 2018 D rug development needs a new storyline. Although pharmaceutical companies spend billions of dollars to develop new therapeutics, only one out of every ten candidates survives clinical trials, and the majority fail due to a lack of efficacy and/or safety. Genetics may rewrite that story. Preclinical studies model dis- eases using cell culture or animal models to predict drug efficacy and safety, and, as a result, most drug candidates enter clinical trials without clear evidence of the targeted pathway's relevance to the disease in humans. Human genetics, on the other hand, uses real-world data to decipher the riddles of human pathology. "When we've looked at using genetics broadly to recapitulate drug activity it's actually been a pretty good story," said Joshua Denny, M.D., professor of biomedi- cal informatics and medicine at Vanderbilt University Medical Center. "[The data] really suggests that genetics are helpful in determining what drugs work in a disease." For example, in 2013 Okada et al., recapitulated 27 genes targeted by drugs currently approved for rheumatoid arthritis using a genome-wide association study (GWAS) meta-analysis. Down the Rabbit Hole However, over the past decade, scientists have followed GWAS down the rabbithole only to discover that they need a new paradigm to explain the most prevalent dis- eases. While GWAS works well for diseases caused by single, rare mutations with high penetrance, the black and white days of "simple" monogenic traits have given way to a more complex framework where multiple genes, and even environmental factors, contribute to disease. According to Marylyn Ritchie, Ph.D., professor and director of biomedical and trans- lational informatics at Geisinger Health System, the past decade of genetics research "has actually shown us that even traits we would have previously said are simple, like Mendelian traits, turn out to be complex." The genetics of disease becomes "curiouser and curiouser" as variations in penetrance and expressivity complicate the pheno- types related to monogenic diseases, while pleiotropic genes influence multiple, seem- ingly unrelated, phenotypes. Meghaan Ferreira, Ph.D. Contributing Editor Genetics Rewriting the Story of Drug Development with PheWAS Adventures in

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2018